An Jian-Xiong, Liu Hui, Chen Ruo-Wen, Wang Yong, Zhao Wen-Xing, Eastwood Derek, Williams John P
Department of Anesthesiology, Pain Medicine & Critical Care Medicine, Aviation General Hospital of China Medical University & Beijing Institute of Translational Medicine, Chinese Academy of Sciences.
Department of Anesthesiology, Weifang Medical University, Beijing, People's Republic of China.
J Pain Res. 2018 Jan 31;11:255-263. doi: 10.2147/JPR.S140369. eCollection 2018.
The aim of this study was to evaluate the therapeutic effect of computed tomography (CT)-guided percutaneous ozone injection for refractory trigeminal neuralgia.
A retrospective evaluation was performed in the study.
The study was conducted at a university hospital pain center.
A total of 29 patients with a clinical diagnosis of refractory trigeminal neuralgia were enrolled. All patients were treated with a percutaneous ozone injection and one patient was excluded. There were 21 patients with classical trigeminal neuralgia (group A) and seven patients with painful trigeminal neuropathy caused by post-herpetic neuralgia (group B). The percutaneous injection was an oxygen-ozone mixture at an ozone concentration of 30 μg/mL into the Gasserian ganglion performed under CT guidance. The number of procedures performed varied from one to as many as 16. Outcomes were evaluated using visual analog scale (VAS) pain scores.
The combined VAS scores were 7.11 ± 1.23 pretreatment, 2.86 ± 1.69 posttreatment ( < 0.05) and 3.25 ± 2.01 after 6-month follow-up ( < 0.05). In group A, the VAS scores were 7.10 ± 1.04 pretreatment and 2.90 ± 1.84 posttreatment ( < 0.05). In group B, the VAS scores were 7.14 ± 1.77 pretreatment and 2.71 ± 1.25 posttreatment ( < 0.05). After 6-months follow-up, the VAS score was 3.38 ± 2.18 in group A and 2.86 ± 1.46 in group B, a decrease compared to pretreatment ( < 0.05). VAS of Group A and B showed no difference not only in pretreatment but also in postreatment and follow-up.
Percutaneous ozone injection is a safe and effective treatment for patients with refractory trigeminal neuralgia.
本研究旨在评估计算机断层扫描（CT）引导下经皮臭氧注射治疗难治性三叉神经痛的疗效。
本研究进行回顾性评估。
研究在一家大学医院疼痛中心进行。
共纳入29例临床诊断为难治性三叉神经痛的患者。所有患者均接受经皮臭氧注射治疗，1例患者被排除。其中有21例典型三叉神经痛患者（A组）和7例由带状疱疹后神经痛引起的疼痛性三叉神经病变患者（B组）。经皮注射是在CT引导下将臭氧浓度为30μg/mL的氧气 - 臭氧混合气体注入半月神经节。治疗次数从1次到多达16次不等。使用视觉模拟量表（VAS）疼痛评分评估结果。
治疗前VAS综合评分为7.11±1.23，治疗后为2.86±1.69（P<0.05），6个月随访后为3.25±2.01（P<0.05）。A组治疗前VAS评分为7.10±1.04，治疗后为2.90±1.84（P<0.05）。B组治疗前VAS评分为7.14±1.77，治疗后为2.71±1.25（P<0.05）。6个月随访后，A组VAS评分为3.38±2.18，B组为2.86±1.46，与治疗前相比均降低（P<0.05）。A组和B组的VAS评分在治疗前、治疗后及随访时均无差异。
经皮臭氧注射是治疗难治性三叉神经痛患者的一种安全有效的方法。
